文献速递肝胆胰外科

未来残肝功能预测门静脉栓塞后增生反应

Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization.
PubMed 文献 · Surgery · 2017-03-30

本研究纳入63例术前接受门静脉栓塞(PVE)并CT成像的患者,用99mTc-甲溴芬宁肝胆闪烁显像测定PVE前后未来残肝功能。结果显示,未化疗患者PVE前未来残肝功能≥1.72%/min/m2可识别PVE后3周达到安全功能 cutoff(2.7%/min/m2)者,AUC=0.820;化疗患者预测价值较低(AUC=0.618)。

要点

  • PVE前未来残肝功能可预测PVE后功能增生是否充分,尤其适用于未化疗患者。
  • 未化疗患者PVE前未来残肝功能≥1.72%/min/m2提示PVE后3周可达安全功能 cutoff。
  • 对PVE增生不足者,可考虑ALPPS等更强增生策略。

核心结论

  • PVE前肝胆闪烁显像评估的未来残肝功能可预测PVE后功能增生不足,尤其在未化疗患者中。

研究设计与样本

  • 纳入63例接受术前PVE并CT成像的患者,用99mTc-甲溴芬宁肝胆闪烁显像测定PVE前后未来残肝功能。
  • 采用受试者工作特征(ROC)分析PVE前未来残肝功能,识别PVE后达到安全功能 cutoff(2.7%/min/m2)的患者。

主要发现

  • PVE前未来残肝功能平均为1.80%±0.45%/min/m2,PVE后增至2.89%±0.97%/min/m2。
  • 33例未化疗患者中,PVE前未来残肝功能≥1.72%/min/m2可识别PVE后3周达到安全功能 cutoff 者,AUC=0.820。
  • 30例接受新辅助化疗患者中,预测价值较低,AUC=0.618。
  • 63例中45例接受肝切除,其中5例发生术后肝衰竭;5例中4例PVE后未来残肝功能低于安全切除 cutoff。

关键数值与推荐

  • PVE后未来残肝功能安全 cutoff 为2.7%/min/m2。
  • 未化疗患者PVE前未来残肝功能≥1.72%/min/m2可预测PVE后3周达到安全功能 cutoff,AUC=0.820。

临床怎么用

  • PVE前可用肝胆闪烁显像评估未来残肝功能,预判PVE后功能增生是否充分。
  • 对预测增生不足者,可考虑ALPPS等诱导更强增生反应的策略。

局限性

  • 化疗患者中PVE前未来残肝功能的预测价值较低(AUC=0.618)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preoperative portal vein embolization is widely used to increase the future remnant liver. Identification of nonresponders to portal vein embolization is essential because these patients may benefit from associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), which induces a more powerful hypertrophy response. 99mTc-mebrofenin hepatobiliary scintigraphy is a quantitative method for assessment of future remnant liver function with a calculated cutoff value for the prediction of postoperative liver failure. The aim of this study was to analyze future remnant liver function before portal vein embolization to predict sufficient functional hypertrophy response after portal vein embolization. METHODS: Sixty-three patients who underwent preoperative portal vein embolization and computed tomography imaging were included. Hepatobiliary scintigraphy was performed to determine pre-portal vein embolization and post-portal vein embolization future remnant liver function. Receiver operator characteristic analysis of pre-portal vein embolization future remnant liver function was performed to identify patients who would meet the post-portal vein embolization cutoff value for sufficient function (ie, 2.7%/min/m2). RESULTS: Mean pre-portal vein embolization future remnant liver function was 1.80% ± 0.45%/min/m2 and increased to 2.89% ± 0.97%/min/m2 post-portal vein embolization. Receiver operator characteristic analysis in 33 patients who did not receive chemotherapy revealed that a pre-portal vein embolization future remnant liver function of ≥1.72%/min/m2 was able to identify patients who would meet the safe future remnant liver function cutoff value 3 weeks after portal vein embolization (area under the curve = 0.820). The predictive value was less pronounced in 30 patients treated with neoadjuvant chemotherapy (area under the curve = 0.618). A total of 45 of 63 patients underwent liver resection, of whom 5 of 45 developed postoperative liver failure; 4 of 5 patients had a post-portal vein embolization future remnant liver function below the cutoff value for safe resection. CONCLUSION: When selecting patients for portal vein embolization, future remnant liver function assessed with hepatobiliary scintigraphy can be used as a predictor of insufficient functional hypertrophy after portal vein embolization, especially in nonchemotherapy patients. These patients are potential candidates for ALPPS.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Cieslak KP, Huisman F, Bais T, et al. Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization. Surgery. 2017. PMID: 28365007. doi:10.1016/j.surg.2016.12.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。